Q&A: Can oncolytic viruses make a comeback? Experts dissect clinical failures and outline path forward
In the eight years since the FDA first approved an oncolytic virus as a cancer therapy, developers have been striving — and largely failing — to bring …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
